These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 21428178)

  • 21. Ischemic mitral valve regurgitation in patients with depressed ventricular function: cardiac geometrical and myocardial perfusion evaluation with magnetic resonance imaging.
    D'Ancona G; Biondo D; Mamone G; Marrone G; Pirone F; Santise G; Sciacca S; Pilato M
    Eur J Cardiothorac Surg; 2008 Nov; 34(5):964-8. PubMed ID: 18774304
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms.
    Nanni S; Melandri G; Hanemaaijer R; Cervi V; Tomasi L; Altimari A; Van Lent N; Tricoci P; Bacchi L; Branzi A
    Transl Res; 2007 Mar; 149(3):137-44. PubMed ID: 17320799
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circulating matrix metalloproteinase-3 and metalloproteinase-9 and tissue Doppler measures of diastolic dysfunction to risk stratify patients with systolic heart failure.
    Buralli S; Dini FL; Ballo P; Conti U; Fontanive P; Duranti E; Metelli MR; Marzilli M; Taddei S
    Am J Cardiol; 2010 Mar; 105(6):853-6. PubMed ID: 20211331
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Matrix metalloproteinases and inflammatory markers in coronary artery ectasia: their relationship to severity of coronary artery ectasia.
    Dogan A; Tuzun N; Turker Y; Akcay S; Kaya S; Ozaydin M
    Coron Artery Dis; 2008 Dec; 19(8):559-63. PubMed ID: 19005290
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Urinary levels of matrix metalloproteinase 9 and 2 and tissue inhibitor of matrix metalloproteinase in patients with coronary artery disease.
    Fitzsimmons PJ; Forough R; Lawrence ME; Gantt DS; Rajab MH; Kim H; Weylie B; Spiekerman AM; Dehmer GJ
    Atherosclerosis; 2007 Sep; 194(1):196-203. PubMed ID: 16942771
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of matrix metalloproteinase and their inhibitors on atrial myocardial structural remodeling.
    Wang W; Zhang HT; Yang XL
    J Cardiovasc Med (Hagerstown); 2013 Apr; 14(4):265-9. PubMed ID: 22929563
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Positive correlations between circulating adiponectin and MMP2 in preeclampsia pregnant.
    Eleuterio NM; Palei AC; Rangel Machado JS; Tanus-Santos JE; Cavalli RC; Sandrim VC
    Pregnancy Hypertens; 2015 Apr; 5(2):205-8. PubMed ID: 25943646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease.
    Ulrich D; Hrynyschyn K; Pallua N
    Plast Reconstr Surg; 2003 Oct; 112(5):1279-86. PubMed ID: 14504511
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heavy smoking before coronary surgical procedures affects the native matrix metalloproteinase-2 and matrix metalloproteinase-9 gene expression in saphenous vein conduits.
    Yongxin S; Wenjun D; Qiang W; Yunqing S; Liming Z; Chunsheng W
    Ann Thorac Surg; 2013 Jan; 95(1):55-61. PubMed ID: 23146278
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early measurements of plasma matrix metalloproteinase-2 predict infarct size and ventricular dysfunction in ST-elevation myocardial infarction.
    Nilsson L; Hallén J; Atar D; Jonasson L; Swahn E
    Heart; 2012 Jan; 98(1):31-6. PubMed ID: 21727201
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High variability in MMP2/TIMP2 and MMP9/TIMP1 expression in secondary liver tumors.
    Avădanei R; Căruntu ID; Amălinei C; Lozneanu L; Balan R; Grigoraş A; Ciobanu Apostol D; Giuşcă SE
    Rom J Morphol Embryol; 2013; 54(3):479-85. PubMed ID: 24068394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New insights into molecular mechanisms of diffuse coronary ectasiae: a possible role for VEGF.
    Savino M; Parisi Q; Biondi-Zoccai GG; Pristipino C; Cianflone D; Crea F
    Int J Cardiol; 2006 Jan; 106(3):307-12. PubMed ID: 16337037
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [In patients with coronary artery disease and left ventricular contractile insufficiency the pathogenicity of smoking associates with imbalance in metabolism of homocysteine].
    Strauss E; Supiński W; Głuszek J; Pawlak AL
    Przegl Lek; 2006; 63(10):951-6. PubMed ID: 17288192
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure?
    Collier P; Watson CJ; Voon V; Phelan D; Jan A; Mak G; Martos R; Baugh JA; Ledwidge MT; McDonald KM
    Eur J Heart Fail; 2011 Oct; 13(10):1087-95. PubMed ID: 21719449
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TIMP2 deficiency accelerates adverse post-myocardial infarction remodeling because of enhanced MT1-MMP activity despite lack of MMP2 activation.
    Kandalam V; Basu R; Abraham T; Wang X; Soloway PD; Jaworski DM; Oudit GY; Kassiri Z
    Circ Res; 2010 Mar; 106(4):796-808. PubMed ID: 20056917
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Imbalance between matrix metalloproteinases (MMP-9 and MMP-2) and tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in acute respiratory distress syndrome patients.
    Lanchou J; Corbel M; Tanguy M; Germain N; Boichot E; Theret N; Clement B; Lagente V; Malledant Y
    Crit Care Med; 2003 Feb; 31(2):536-42. PubMed ID: 12576963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma MMP-9 and TIMP-1 levels on ICU admission are associated with 30-day survival.
    Jordakieva G; Budge-Wolfram RM; Budinsky AC; Nikfardjam M; Delle-Karth G; Girard A; Godnic-Cvar J; Crevenna R; Heinz G
    Wien Klin Wochenschr; 2021 Feb; 133(3-4):86-95. PubMed ID: 31932967
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome.
    Inokubo Y; Hanada H; Ishizaka H; Fukushi T; Kamada T; Okumura K
    Am Heart J; 2001 Feb; 141(2):211-7. PubMed ID: 11174334
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of the tissue inhibitor of metalloproteinase-3 by transplanted VSMCs modifies heart structure and function after myocardial infarction.
    Jia ZB; Tian H; Kang K; Miao HZ; Liu KY; Jiang SL; Wang LP
    Transpl Immunol; 2014 May; 30(4):149-58. PubMed ID: 24727088
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metalloproteinases-2, -9 and TIMP-1 expression in stable and unstable coronary plaques undergoing PCI.
    Fiotti N; Altamura N; Orlando C; Simi L; Reimers B; Pascotto P; Zingone B; Pascotto A; Serio M; Guarnieri G; Giansante C
    Int J Cardiol; 2008 Jul; 127(3):350-7. PubMed ID: 17706812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.